CA3005695A1 - Methods for predicting response to anti-tnf therapy - Google Patents
Methods for predicting response to anti-tnf therapy Download PDFInfo
- Publication number
- CA3005695A1 CA3005695A1 CA3005695A CA3005695A CA3005695A1 CA 3005695 A1 CA3005695 A1 CA 3005695A1 CA 3005695 A CA3005695 A CA 3005695A CA 3005695 A CA3005695 A CA 3005695A CA 3005695 A1 CA3005695 A1 CA 3005695A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- target molecule
- expression
- sample
- tnf therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 134
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 121
- 230000004044 response Effects 0.000 title claims abstract description 92
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 122
- 230000014509 gene expression Effects 0.000 claims abstract description 118
- 239000000090 biomarker Substances 0.000 claims abstract description 68
- 230000001363 autoimmune Effects 0.000 claims abstract description 40
- 230000001404 mediated effect Effects 0.000 claims abstract description 39
- 230000001105 regulatory effect Effects 0.000 claims abstract description 26
- 108010050904 Interferons Proteins 0.000 claims abstract description 24
- 102000014150 Interferons Human genes 0.000 claims abstract description 24
- 229940079322 interferon Drugs 0.000 claims abstract description 23
- 238000011282 treatment Methods 0.000 claims abstract description 20
- 210000003714 granulocyte Anatomy 0.000 claims abstract description 15
- 238000012544 monitoring process Methods 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 49
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 41
- 208000035475 disorder Diseases 0.000 claims description 38
- -1 IF16 Proteins 0.000 claims description 37
- 102100040618 Eosinophil cationic protein Human genes 0.000 claims description 35
- 102100032131 Lymphocyte antigen 6E Human genes 0.000 claims description 35
- 102100032947 UMP-CMP kinase 2, mitochondrial Human genes 0.000 claims description 34
- 102100020726 Ubl carboxyl-terminal hydrolase 18 Human genes 0.000 claims description 33
- 101000942626 Homo sapiens UMP-CMP kinase 2, mitochondrial Proteins 0.000 claims description 32
- 102100033749 Radical S-adenosyl methionine domain-containing protein 2 Human genes 0.000 claims description 32
- 210000000440 neutrophil Anatomy 0.000 claims description 31
- 102000004169 proteins and genes Human genes 0.000 claims description 31
- 102100034217 Non-secretory ribonuclease Human genes 0.000 claims description 30
- 101000967216 Homo sapiens Eosinophil cationic protein Proteins 0.000 claims description 29
- 101000657037 Homo sapiens Radical S-adenosyl methionine domain-containing protein 2 Proteins 0.000 claims description 29
- 101000644847 Homo sapiens Ubl carboxyl-terminal hydrolase 18 Proteins 0.000 claims description 29
- 102100027621 2'-5'-oligoadenylate synthase 2 Human genes 0.000 claims description 28
- 102100026227 Interferon-induced protein with tetratricopeptide repeats 1B Human genes 0.000 claims description 28
- 102100027769 2'-5'-oligoadenylate synthase 1 Human genes 0.000 claims description 27
- 101001055245 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 1B Proteins 0.000 claims description 27
- 101001008907 Homo sapiens 2'-5'-oligoadenylate synthase 1 Proteins 0.000 claims description 26
- 101001065568 Homo sapiens Lymphocyte antigen 6E Proteins 0.000 claims description 26
- 102100035389 2'-5'-oligoadenylate synthase 3 Human genes 0.000 claims description 25
- 101000711744 Homo sapiens Non-secretory ribonuclease Proteins 0.000 claims description 25
- 101001008910 Homo sapiens 2'-5'-oligoadenylate synthase 2 Proteins 0.000 claims description 24
- 101000597332 Homo sapiens 2'-5'-oligoadenylate synthase 3 Proteins 0.000 claims description 24
- 230000002349 favourable effect Effects 0.000 claims description 24
- 102100033174 Neutrophil elastase Human genes 0.000 claims description 23
- 102100035405 Neutrophil gelatinase-associated lipocalin Human genes 0.000 claims description 23
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 claims description 22
- 102100030009 Azurocidin Human genes 0.000 claims description 21
- 102100036348 Neutrophil defensin 4 Human genes 0.000 claims description 21
- 102100025470 Carcinoembryonic antigen-related cell adhesion molecule 8 Human genes 0.000 claims description 20
- 101000990908 Homo sapiens Neutrophil collagenase Proteins 0.000 claims description 20
- 102100032241 Lactotransferrin Human genes 0.000 claims description 20
- 102100030411 Neutrophil collagenase Human genes 0.000 claims description 20
- 102100025975 Cathepsin G Human genes 0.000 claims description 19
- 102100027367 Cysteine-rich secretory protein 3 Human genes 0.000 claims description 19
- 101000793686 Homo sapiens Azurocidin Proteins 0.000 claims description 19
- 101000933179 Homo sapiens Cathepsin G Proteins 0.000 claims description 18
- 101000726258 Homo sapiens Cysteine-rich secretory protein 3 Proteins 0.000 claims description 18
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 claims description 18
- 108010032816 bactericidal permeability increasing protein Proteins 0.000 claims description 18
- 102000052586 bactericidal permeability increasing protein Human genes 0.000 claims description 18
- 108020004999 messenger RNA Proteins 0.000 claims description 17
- 101001052004 Escherichia phage T5 L-shaped tail fiber protein pb1 Proteins 0.000 claims description 16
- 230000006872 improvement Effects 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- 230000008859 change Effects 0.000 claims description 15
- 210000004369 blood Anatomy 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 11
- 238000003559 RNA-seq method Methods 0.000 claims description 10
- 239000002299 complementary DNA Substances 0.000 claims description 9
- 108020001507 fusion proteins Proteins 0.000 claims description 9
- 102000037865 fusion proteins Human genes 0.000 claims description 9
- 108010008165 Etanercept Proteins 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 7
- 102100027354 Interferon alpha-inducible protein 6 Human genes 0.000 claims description 7
- 230000008901 benefit Effects 0.000 claims description 7
- 230000002068 genetic effect Effects 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 238000012163 sequencing technique Methods 0.000 claims description 6
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 5
- 101001082070 Homo sapiens Interferon alpha-inducible protein 6 Proteins 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 229960002964 adalimumab Drugs 0.000 claims description 5
- 239000005557 antagonist Substances 0.000 claims description 5
- 229960000403 etanercept Drugs 0.000 claims description 5
- 238000012165 high-throughput sequencing Methods 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 230000036407 pain Effects 0.000 claims description 5
- 238000003753 real-time PCR Methods 0.000 claims description 5
- 230000008961 swelling Effects 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 229960000598 infliximab Drugs 0.000 claims description 4
- 238000003196 serial analysis of gene expression Methods 0.000 claims description 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 3
- 102000014914 Carrier Proteins Human genes 0.000 claims description 3
- 108091006020 Fc-tagged proteins Proteins 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims description 3
- 108091008324 binding proteins Proteins 0.000 claims description 3
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims description 3
- 229960001058 bupropion Drugs 0.000 claims description 3
- 229960003115 certolizumab pegol Drugs 0.000 claims description 3
- 229940090100 cimzia Drugs 0.000 claims description 3
- 229940073621 enbrel Drugs 0.000 claims description 3
- 229960001743 golimumab Drugs 0.000 claims description 3
- 229940048921 humira Drugs 0.000 claims description 3
- 229960001476 pentoxifylline Drugs 0.000 claims description 3
- 229940116176 remicade Drugs 0.000 claims description 3
- 229940068638 simponi Drugs 0.000 claims description 3
- 150000003384 small molecules Chemical class 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010061818 Disease progression Diseases 0.000 claims description 2
- 208000012528 Juvenile dermatomyositis Diseases 0.000 claims description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 201000010415 childhood type dermatomyositis Diseases 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 230000005750 disease progression Effects 0.000 claims description 2
- 238000009396 hybridization Methods 0.000 claims description 2
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 238000011269 treatment regimen Methods 0.000 claims description 2
- 101000914320 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 claims 5
- 101000929203 Homo sapiens Neutrophil defensin 4 Proteins 0.000 claims 5
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 claims 5
- 230000001419 dependent effect Effects 0.000 claims 5
- 102100034343 Integrase Human genes 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000523 sample Substances 0.000 description 46
- 235000018102 proteins Nutrition 0.000 description 30
- 230000027455 binding Effects 0.000 description 22
- 108010051335 Lipocalin-2 Proteins 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 18
- 238000010200 validation analysis Methods 0.000 description 18
- 101710190844 Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 description 15
- 101710117154 Neutrophil defensin 4 Proteins 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 14
- SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 description 14
- 102000018594 Tumour necrosis factor Human genes 0.000 description 13
- 108050007852 Tumour necrosis factor Proteins 0.000 description 13
- 102000003960 Ligases Human genes 0.000 description 11
- 108090000364 Ligases Proteins 0.000 description 11
- 230000009266 disease activity Effects 0.000 description 11
- 239000003435 antirheumatic agent Substances 0.000 description 8
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 239000013610 patient sample Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 108010086241 2',5'-Oligoadenylate Synthetase Proteins 0.000 description 5
- 102000007445 2',5'-Oligoadenylate Synthetase Human genes 0.000 description 5
- 101710191360 Eosinophil cationic protein Proteins 0.000 description 5
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 5
- 102100039953 Interferon-induced protein 44-like Human genes 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 101150112649 fdr gene Proteins 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 4
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 4
- 101710153383 Ubl carboxyl-terminal hydrolase 18 Proteins 0.000 description 4
- 239000013068 control sample Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000009258 post-therapy Methods 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- GTVAUHXUMYENSK-RWSKJCERSA-N 2-[3-[(1r)-3-(3,4-dimethoxyphenyl)-1-[(2s)-1-[(2s)-2-(3,4,5-trimethoxyphenyl)pent-4-enoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H](CC=C)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 GTVAUHXUMYENSK-RWSKJCERSA-N 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
- 101000959664 Homo sapiens Interferon-induced protein 44-like Proteins 0.000 description 3
- 101001082065 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 1 Proteins 0.000 description 3
- 102100027355 Interferon-induced protein with tetratricopeptide repeats 1 Human genes 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 101710157879 Lymphocyte antigen 6E Proteins 0.000 description 3
- 101710118518 Non-secretory ribonuclease Proteins 0.000 description 3
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 3
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 3
- 101710094907 Radical S-adenosyl methionine domain-containing protein 2 Proteins 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 102100020797 UMP-CMP kinase Human genes 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 229960000106 biosimilars Drugs 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108010037277 thymic shared antigen-1 Proteins 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 102100036618 ATP-binding cassette sub-family A member 13 Human genes 0.000 description 2
- 101710154607 Azurocidin Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 108010050456 Eosinophil-Derived Neurotoxin Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 2
- 101000929660 Homo sapiens ATP-binding cassette sub-family A member 13 Proteins 0.000 description 2
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 2
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 2
- 101100182720 Homo sapiens LY6E gene Proteins 0.000 description 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 2
- 101710169201 Interferon alpha-inducible protein 6 Proteins 0.000 description 2
- 101710142533 Interferon-induced protein 44-like Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102100038610 Myeloperoxidase Human genes 0.000 description 2
- 108090000235 Myeloperoxidases Proteins 0.000 description 2
- 102000056189 Neutrophil collagenases Human genes 0.000 description 2
- 108030001564 Neutrophil collagenases Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 102100038081 Signal transducer CD24 Human genes 0.000 description 2
- 102100022719 Solute carrier family 2, facilitated glucose transporter member 5 Human genes 0.000 description 2
- 101710100179 UMP-CMP kinase Proteins 0.000 description 2
- 101710119674 UMP-CMP kinase 2, mitochondrial Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 2
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000011222 transcriptome analysis Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 101710109227 2'-5'-oligoadenylate synthase 1 Proteins 0.000 description 1
- 101710109225 2'-5'-oligoadenylate synthase 2 Proteins 0.000 description 1
- 101710109224 2'-5'-oligoadenylate synthase 3 Proteins 0.000 description 1
- LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 108050004095 Adenylate kinase 4, mitochondrial Proteins 0.000 description 1
- 108050000848 Adenylate kinase 7 Proteins 0.000 description 1
- 108050004092 Adenylate kinase isoenzyme 1 Proteins 0.000 description 1
- 102100033393 Anillin Human genes 0.000 description 1
- 102100040006 Annexin A1 Human genes 0.000 description 1
- 101100038001 Arabidopsis thaliana RNS3 gene Proteins 0.000 description 1
- 108010032951 Ataxin2 Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100026337 BAI1-associated protein 3 Human genes 0.000 description 1
- 101710049498 BAIAP3 Proteins 0.000 description 1
- 102100033735 Bactericidal permeability-increasing protein Human genes 0.000 description 1
- 206010070918 Bone deformity Diseases 0.000 description 1
- 102000001967 Branched-chain aminotransferases Human genes 0.000 description 1
- 108050009223 Branched-chain aminotransferases Proteins 0.000 description 1
- 102100026437 Branched-chain-amino-acid aminotransferase, cytosolic Human genes 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- 102000049320 CD36 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 102100035351 Cadherin-related family member 2 Human genes 0.000 description 1
- 101100208421 Candida albicans (strain SC5314 / ATCC MYA-2876) TMP1 gene Proteins 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 108090000617 Cathepsin G Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100037328 Chitotriosidase-1 Human genes 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108700040183 Complement C1 Inhibitor Proteins 0.000 description 1
- 102000055157 Complement C1 Inhibitor Human genes 0.000 description 1
- 101710126281 Cysteine-rich secretory protein 3 Proteins 0.000 description 1
- 101710191477 Cytidylate kinase 2 Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 101100155201 Drosophila melanogaster ubl gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700016749 Eosinophil Cationic Proteins 0.000 description 1
- 206010049466 Erythroblastosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100035716 Glycophorin-A Human genes 0.000 description 1
- 108091005250 Glycophorins Proteins 0.000 description 1
- 102100035688 Guanylate-binding protein 1 Human genes 0.000 description 1
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
- 102100023357 Histone deacetylase complex subunit SAP30 Human genes 0.000 description 1
- 101000694718 Homo sapiens Amine oxidase [flavin-containing] A Proteins 0.000 description 1
- 101000732632 Homo sapiens Anillin Proteins 0.000 description 1
- 101000959738 Homo sapiens Annexin A1 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000871785 Homo sapiens Bactericidal permeability-increasing protein Proteins 0.000 description 1
- 101000766268 Homo sapiens Branched-chain-amino-acid aminotransferase, cytosolic Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101000737811 Homo sapiens Cadherin-related family member 2 Proteins 0.000 description 1
- 101000879661 Homo sapiens Chitotriosidase-1 Proteins 0.000 description 1
- 101000865408 Homo sapiens Double-stranded RNA-specific adenosine deaminase Proteins 0.000 description 1
- 101001001336 Homo sapiens Guanylate-binding protein 1 Proteins 0.000 description 1
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
- 101000686001 Homo sapiens Histone deacetylase complex subunit SAP30 Proteins 0.000 description 1
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101000598002 Homo sapiens Interferon regulatory factor 1 Proteins 0.000 description 1
- 101000926535 Homo sapiens Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 1
- 101100261259 Homo sapiens LTF gene Proteins 0.000 description 1
- 101000578928 Homo sapiens Macrophage immunometabolism regulator Proteins 0.000 description 1
- 101000636210 Homo sapiens Matrix-remodeling-associated protein 7 Proteins 0.000 description 1
- 101001014566 Homo sapiens Membrane-spanning 4-domains subfamily A member 3 Proteins 0.000 description 1
- 101001090860 Homo sapiens Myeloblastin Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101001121539 Homo sapiens P2Y purinoceptor 14 Proteins 0.000 description 1
- 101000734351 Homo sapiens PDZ and LIM domain protein 1 Proteins 0.000 description 1
- 101001136986 Homo sapiens Proteasome subunit beta type-8 Proteins 0.000 description 1
- 101000998897 Homo sapiens Serine protease HTRA3 Proteins 0.000 description 1
- 101000711475 Homo sapiens Serpin B10 Proteins 0.000 description 1
- 101000631760 Homo sapiens Sodium channel protein type 1 subunit alpha Proteins 0.000 description 1
- 101000818832 Homo sapiens Zinc finger protein 608 Proteins 0.000 description 1
- 102100027004 Inhibin beta A chain Human genes 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102100036981 Interferon regulatory factor 1 Human genes 0.000 description 1
- 101710082618 Interferon-induced protein with tetratricopeptide repeats 1B Proteins 0.000 description 1
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 108010028275 Leukocyte Elastase Proteins 0.000 description 1
- 108010009489 Lysosomal-Associated Membrane Protein 3 Proteins 0.000 description 1
- 102100028329 Macrophage immunometabolism regulator Human genes 0.000 description 1
- 102100030775 Matrix-remodeling-associated protein 7 Human genes 0.000 description 1
- 102100032517 Membrane-spanning 4-domains subfamily A member 3 Human genes 0.000 description 1
- 101100208706 Mus musculus Usp18 gene Proteins 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102000013901 Nucleoside diphosphate kinase Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 102100025808 P2Y purinoceptor 14 Human genes 0.000 description 1
- 102100034819 PDZ and LIM domain protein 1 Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 229940122344 Peptidase inhibitor Drugs 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102100035760 Proteasome subunit beta type-8 Human genes 0.000 description 1
- 238000011531 Quantitect SYBR Green PCR kit Methods 0.000 description 1
- 101710192196 Ribonuclease 2 Proteins 0.000 description 1
- 101710192197 Ribonuclease 3 Proteins 0.000 description 1
- 101150103815 Rnase3 gene Proteins 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 101150097162 SERPING1 gene Proteins 0.000 description 1
- 102000037054 SLC-Transporter Human genes 0.000 description 1
- 108091006207 SLC-Transporter Proteins 0.000 description 1
- 108091006301 SLC2A5 Proteins 0.000 description 1
- 101100153788 Schizosaccharomyces pombe (strain 972 / ATCC 24843) tpx1 gene Proteins 0.000 description 1
- 102100033197 Serine protease HTRA3 Human genes 0.000 description 1
- 108050000761 Serpin Proteins 0.000 description 1
- 102000008847 Serpin Human genes 0.000 description 1
- 102100034012 Serpin B10 Human genes 0.000 description 1
- 102100028910 Sodium channel protein type 1 subunit alpha Human genes 0.000 description 1
- 101710104292 Solute carrier family 2, facilitated glucose transporter member 5 Proteins 0.000 description 1
- 101150033527 TNF gene Proteins 0.000 description 1
- 101150048440 TSA1 gene Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 101710201873 UMP-CMP kinase 2 Proteins 0.000 description 1
- 108030007083 UMP/CMP kinases Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 102100021354 Zinc finger protein 608 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 230000008777 canonical pathway Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Substances ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 108010000742 dTMP kinase Proteins 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000002557 hidradenitis Diseases 0.000 description 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 description 1
- 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 108010057248 oncogene proteins v-ets Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 102000043160 thymidylate kinase family Human genes 0.000 description 1
- 108091084369 thymidylate kinase family Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Primary Health Care (AREA)
- Signal Processing (AREA)
- Biomedical Technology (AREA)
- Artificial Intelligence (AREA)
- Bioethics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Evolutionary Computation (AREA)
- Software Systems (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Theoretical Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1521357.2 | 2015-12-03 | ||
| GBGB1521357.2A GB201521357D0 (en) | 2015-12-03 | 2015-12-03 | Methods for predicting response to anti-TNF therapy |
| PCT/GB2016/053798 WO2017093750A1 (en) | 2015-12-03 | 2016-12-02 | Methods for predicting response to anti-tnf therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3005695A1 true CA3005695A1 (en) | 2017-06-08 |
Family
ID=55234362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3005695A Abandoned CA3005695A1 (en) | 2015-12-03 | 2016-12-02 | Methods for predicting response to anti-tnf therapy |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190367984A1 (enExample) |
| EP (1) | EP3384044A1 (enExample) |
| JP (1) | JP2018537100A (enExample) |
| CN (1) | CN108291261A (enExample) |
| AU (1) | AU2016364003A1 (enExample) |
| CA (1) | CA3005695A1 (enExample) |
| GB (1) | GB201521357D0 (enExample) |
| WO (1) | WO2017093750A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108290058B (zh) | 2015-09-17 | 2023-05-16 | 美国安进公司 | 使用il23途径生物标志物预测il23拮抗剂的临床应答 |
| WO2019018440A1 (en) * | 2017-07-17 | 2019-01-24 | The Broad Institute, Inc. | HUMAN COLON CELL ATLAS IN GOOD HEALTH AND WITH HEMORRHAGIC RECTO-COLITIS |
| CN108047327B (zh) * | 2017-11-29 | 2020-08-07 | 中国医学科学院北京协和医院 | 一种检测骨关节炎的生物标志物及其应用 |
| US20200399698A1 (en) * | 2018-02-19 | 2020-12-24 | Genefron Ltd. | Methods of determining response to tnf alpha blockers |
| EP3765634A4 (en) | 2018-03-16 | 2021-12-01 | Scipher Medicine Corporation | METHODS AND SYSTEMS FOR PREDICTING THE RESPONSE TO ANTI-TNF THERAPIES |
| US20210104321A1 (en) * | 2018-11-15 | 2021-04-08 | Ampel Biosolutions, Llc | Machine learning disease prediction and treatment prioritization |
| GB2603294A (en) | 2019-06-27 | 2022-08-03 | Scipher Medicine Corp | Developing classifiers for stratifying patients |
| WO2021067667A1 (en) * | 2019-10-04 | 2021-04-08 | The Regents Of The University Of Michigan | Methods for determining responsiveness to anti-tumor necrosis factor therapy in the treatment of psoriasis |
| KR20230165746A (ko) * | 2020-11-30 | 2023-12-05 | 민데라 코포레이션 | 마이크로니들 디바이스 및 방법, 및 피부 병태 어세이 |
| WO2022190036A2 (en) * | 2021-03-12 | 2022-09-15 | Janssen Biotech, Inc. | Methods for predicting treatment response in ulcerative colitis |
| CN113373218A (zh) * | 2021-08-04 | 2021-09-10 | 杭州浙大迪迅生物基因工程有限公司 | 一组检测人嗜酸性粒细胞阳离子蛋白mRNA表达的引物组和试剂盒 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2069533B1 (en) * | 2006-07-13 | 2012-11-07 | Life Technologies Corporation | Gene expression profiling for identification, monitoring and treatment of multiple sclerosis |
| WO2008132176A2 (en) * | 2007-04-27 | 2008-11-06 | Universite Catholique De Louvain | Method for evaluating the response of an individual to tnf blocking therapy |
| CA2690898A1 (en) * | 2007-06-08 | 2008-12-18 | Biogen Idec Ma Inc. | Biomarkers for predicting anti-tnf responsiveness or non-responsiveness |
| EP2192197A1 (en) * | 2008-11-27 | 2010-06-02 | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg | Predicting clinical response to treatment with a soluble tnf-antagonist or tnf, or a tnf receptor agonist |
| MX353186B (es) * | 2009-09-03 | 2018-01-05 | Genentech Inc | Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide. |
| US20130042333A1 (en) * | 2011-05-06 | 2013-02-14 | Jean-Gabriel JUDDE | Markers for cancer prognosis and therapy and methods of use |
| HU230680B1 (hu) * | 2012-10-19 | 2017-08-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Diagnosztikai eljárás |
| US9809854B2 (en) * | 2012-11-15 | 2017-11-07 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Biomarkers for disease activity and clinical manifestations systemic lupus erythematosus |
-
2015
- 2015-12-03 GB GBGB1521357.2A patent/GB201521357D0/en not_active Ceased
-
2016
- 2016-12-02 CA CA3005695A patent/CA3005695A1/en not_active Abandoned
- 2016-12-02 CN CN201680071029.6A patent/CN108291261A/zh active Pending
- 2016-12-02 AU AU2016364003A patent/AU2016364003A1/en not_active Abandoned
- 2016-12-02 US US15/780,762 patent/US20190367984A1/en not_active Abandoned
- 2016-12-02 WO PCT/GB2016/053798 patent/WO2017093750A1/en not_active Ceased
- 2016-12-02 JP JP2018529050A patent/JP2018537100A/ja active Pending
- 2016-12-02 EP EP16808777.3A patent/EP3384044A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN108291261A (zh) | 2018-07-17 |
| US20190367984A1 (en) | 2019-12-05 |
| AU2016364003A1 (en) | 2018-06-28 |
| GB201521357D0 (en) | 2016-01-20 |
| JP2018537100A (ja) | 2018-12-20 |
| WO2017093750A1 (en) | 2017-06-08 |
| EP3384044A1 (en) | 2018-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190367984A1 (en) | Methods for predicting response to anti-tnf therapy | |
| US20150315643A1 (en) | Blood transcriptional signatures of active pulmonary tuberculosis and sarcoidosis | |
| EP2337864B1 (en) | Biomarkers for predicting the development of chronic autoimmune diseases | |
| CA2889087C (en) | Diagnostic method for predicting response to tnf.alpha. inhibitor | |
| JP6097388B2 (ja) | インフルエンザにおけるリスクの階層化 | |
| CA2988673A1 (en) | Epigenetic chromosome interactions | |
| US11525161B2 (en) | Methods of distinguishing ischemic stroke from intracerebral hemorrhage | |
| JP2013526845A (ja) | サイトカイン標的薬（ＣｙＴＤ）に対する、炎症性疾患に罹患している対象の初期応答または非応答を予測する遺伝子および遺伝子の組み合わせ | |
| Danger et al. | Blood gene expression predicts bronchiolitis obliterans syndrome | |
| WO2013138497A1 (en) | Early detection of tuberculosis treatment response | |
| US20190367964A1 (en) | Dissociation of human tumor to single cell suspension followed by biological analysis | |
| EP3983565B1 (en) | Method of stratifying subjects into sub-groups for therapeutic treatment | |
| JP6347477B2 (ja) | 関節リウマチ患者に対する抗ｉｌ−６受容体抗体治療の有効性予測方法 | |
| EP3464623B1 (en) | Androgen receptor splice variants and androgen deprivation therapy | |
| US20220351806A1 (en) | Biomarker Panels for Guiding Dysregulated Host Response Therapy | |
| US20220290243A1 (en) | Identification of patients that will respond to chemotherapy | |
| US20110177966A1 (en) | method for predicting the response to a treatment with anakinra | |
| US20190234950A1 (en) | Method for the prognosis of multiple myeloma | |
| Hashad et al. | microRNA146a expression in lupus patients with and without renal complications | |
| Noh et al. | Plasma miRNA-214 is a predictive candidate biomarker of progression speed in patients with ALS | |
| Miyamoto et al. | Current Overview of Multi-omics Analyses in Microscopic Polyangiitis and Granulomatosis with Polyangiitis | |
| EP3464614B1 (en) | Method for the prognosis of multiple myeloma | |
| WO2024243224A9 (en) | Multi-omic approach for assessing systemic lupus erythematosus heterogeneity in treatment response | |
| Pollock | Molecular Biomarker Discovery in Psoriatic Arthritis | |
| Patnaik et al. | Enhancer deregulation in TET2 Mutant Clonal Hematopoiesis is associated with increased COVID-19 related inflammation severity and mortality |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20220602 |
|
| FZDE | Discontinued |
Effective date: 20220602 |